Section of Dermatologic Surgery, Ronald O. Perelman Department of Dermatology, New York University Langone Medical Center, New York, NY, United States.
Front Immunol. 2023 Jan 30;14:1084873. doi: 10.3389/fimmu.2023.1084873. eCollection 2023.
Primary cutaneous squamous cell carcinoma (cSCC) is the second most common human cancer with a rising incidence of about 1.8 million in the United States annually. Primary cSCC is usually curable by surgery; however, in some cases, cSCC eventuates in nodal metastasis and death from disease specific death. cSCC results in up to 15,000 deaths each year in the United States. Until recently, non-surgical options for treatment of locally advanced or metastatic cSCC were largely ineffective. With the advent of checkpoint inhibitor immunotherapy, including cemiplimab and pembrolizumab, response rates climbed to 50%, representing a vast improvement over chemotherapeutic agents used previously. Herein, we discuss the phenotype and function of SCC associated Langerhans cells, dendritic cells, macrophages, myeloid derived suppressor cells and T cells as well as SCC-associated lymphatics and blood vessels. Possible role(s) of SCC-associated cytokines in progression and invasion are reviewed. We also discuss the SCC immune microenvironment in the context of currently available and pipeline therapeutics.
原发性皮肤鳞状细胞癌(cSCC)是第二常见的人类癌症,美国每年约有 180 万人的发病率呈上升趋势。原发性 cSCC 通常可通过手术治愈;然而,在某些情况下,cSCC 会导致淋巴结转移和疾病特异性死亡。在美国,每年有多达 15000 人死于 cSCC。直到最近,局部晚期或转移性 cSCC 的非手术治疗选择在很大程度上效果不佳。随着检查点抑制剂免疫疗法的出现,包括 cemiplimab 和 pembrolizumab,反应率攀升至 50%,与之前使用的化疗药物相比有了显著的改善。在此,我们讨论了与 SCC 相关的朗格汉斯细胞、树突状细胞、巨噬细胞、髓系来源的抑制细胞和 T 细胞以及与 SCC 相关的淋巴管和血管的表型和功能。还讨论了 SCC 相关细胞因子在进展和侵袭中的可能作用。我们还讨论了 SCC 免疫微环境在现有治疗药物和药物研发中的情况。